Global Nocturia Market 2025 by Company, Regions, Type and Application, Forecast to 2031

According to our (Global Info Research) latest study, the global Nocturia market size was valued at US$ 2731 million in 2024 and is forecast to a readjusted size of USD 4080 million by 2031 with a CAGR of 5.7% during review period.

Nocturia, also known as nocturnal polyuria, is a medical condition in which patients get a frequent urge to urinate while sleeping at night. It is particularly prevalent among the elderly who often find it difficult to sleep properly. The three broad categories of nocturia are mixed nocturia, bladder storage problems, and nocturnal polyuria.

The global nocturia market, focused on the treatment of nighttime urination, is growing due to an increasing aging population, rising awareness of urinary disorders, and advancements in treatment options. Below are some key trends driving the market:

1. Growing Aging Population

Primary Driver: Nocturia is more prevalent among the elderly, and with a rapidly aging global population, the demand for nocturia treatments is rising. Regions with older populations, such as Europe, North America, and Japan, are seeing increased incidence rates.

Impact: The increase in elderly individuals with nocturia-related issues is expected to drive the demand for pharmaceutical treatments and non-pharmaceutical interventions.

2. Advancements in Treatment Options

Medications: A range of medications, including anticholinergics, desmopressin, and beta-3 adrenergic receptor agonists, are commonly used to treat nocturia. New drug formulations are being developed to reduce side effects and improve efficacy.

Emerging Therapies: Research into gene therapies and targeted molecular therapies is advancing. Additionally, the combination of medications for better symptom control is being explored.

Non-Pharmacological Treatments: Beyond drugs, lifestyle interventions, such as fluid management, bladder training, and devices like bedwetting alarms, are gaining attention as complementary treatments.

3. Increasing Awareness and Diagnosis

Education: Public health campaigns and awareness programs about nocturia are encouraging individuals to seek medical help. Increased awareness is expected to drive the market as more people seek treatment for the condition.

Early Diagnosis: Enhanced diagnostic tools, including better urodynamic testing and digital health platforms for symptom tracking, are improving early detection and management of nocturia.

4. Regional Growth

North America: The U.S. holds the largest market share due to its advanced healthcare infrastructure, higher awareness, and the presence of major pharmaceutical companies. Increasing cases of nocturia among older adults are a significant market driver.

Europe: Aging populations, particularly in Western Europe, are contributing to the increased demand for nocturia treatments. The market in this region benefits from well-established healthcare systems.

Asia-Pacific: The growing healthcare infrastructure in countries like China, Japan, and India is expected to boost market growth. Rising healthcare expenditure and increasing elderly populations in these regions are key factors.

Global core nocturia manufactures include Astellas Pharma, Allergan, Eli Lilly etc. The top 2 companies hold a share about 30%. North America is the largest market, with a share about 40%, followed by Europe and Asia Pacific with the share about 34% and 18%. In terms of product, alpha blockers is the largest segment, with a share over 37%.

This report is a detailed and comprehensive analysis for global Nocturia market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Sale Channels. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.

Key Features:

Global Nocturia market size and forecasts, in consumption value ($ Million), 2020-2031

Global Nocturia market size and forecasts by region and country, in consumption value ($ Million), 2020-2031

Global Nocturia market size and forecasts, by Type and by Sale Channels, in consumption value ($ Million), 2020-2031

Global Nocturia market shares of main players, in revenue ($ Million), 2020-2025

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for Nocturia

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global Nocturia market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Astellas Pharma, Allergan, Ferring Pharmaceuticals, Eli Lilly, GlaxoSmithKline, Sanofi, Pfizer, Abbott, Teva, Mylan, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market segmentation

Nocturia market is split by Type and by Sale Channels. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Sale Channels. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type
Desmopressin
Anticholinergic Drugs
Alpha Blockers
Diuretics
Others

Market segment by Sale Channels
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Market segment by players, this report covers
Astellas Pharma
Allergan
Ferring Pharmaceuticals
Eli Lilly
GlaxoSmithKline
Sanofi
Pfizer
Abbott
Teva
Mylan
Novartis
Johnson & Johnson
Merck
Astra Zeneca
Bristol-Myers Squibb
Hainan Zhonghe Pharmaceutical
Fosun Pharma
Hybio Pharmaceutical
Rechon Life Science AB
Zhejiang Conba Pharmaceutical
Chengdu Leer Pharmaceutical
Nanjing Xingyin Pharmaceutical Group
Sun Pharmaceutical Industries Ltd.
APOTEX INC
Sagent Pharmaceuticals

Market segment by regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia, Italy and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)

South America (Brazil, Rest of South America)

Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 13 chapters:

Chapter 1, to describe Nocturia product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top players of Nocturia, with revenue, gross margin, and global market share of Nocturia from 2020 to 2025.

Chapter 3, the Nocturia competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by Type and by Sale Channels, with consumption value and growth rate by Type, by Sale Channels, from 2020 to 2031

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and Nocturia market forecast, by regions, by Type and by Sale Channels, with consumption value, from 2026 to 2031.

Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.

Chapter 12, the key raw materials and key suppliers, and industry chain of Nocturia.

Chapter 13, to describe Nocturia research findings and conclusion.